A case of an 11-year-old girl diagnosed with OCD developing giggle incontinence following addition of aripiprazole to treatment
Psychiatry and Clinical Psychopharmacology, cilt.28, sa.3, ss.343-345, 2018 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 28 Sayı: 3
- Basım Tarihi: 2018
- Doi Numarası: 10.1080/24750573.2017.1413724
- Dergi Adı: Psychiatry and Clinical Psychopharmacology
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.343-345
- Anahtar Kelimeler: Giggle incontinence, aripirazole, safety, side effects
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Giggle incontinence (GI) is characterized by involuntary and generally unpredictable release of urine during giggling or laughter. It has been suggested that GI may be a centrally mediated disorder and may share a common pathophysiology with narcolepsy and cataplexy. The fact that methylphenidate reduces some symptoms suggests that the condition may be a cataplexy. While alpha 1 and dopamine D2 antagonists exacerbate cataplexy, alpha 1 and dopamine D2 agonists produce a marked improvement. Aripiprazole, frequently used to augment treatment of obsessive compulsive disorder, may have exhibited an alpha 1 and D2 receptor antagonist effect and have caused GI. We describe a case of GI occurring following aripiprazole use in an 11-year-old female obsessive compulsive disorder patient resistant to treatment.